Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,960 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER).
Rummelt C, Grishina O, Schmoor C, Crysandt M, Heuser M, Götze KS, Schlenk RF, Döhner K, Salih HR, Heil G, Müller-Tidow C, Brugger W, Kündgen A, De Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, Al-Ali HK, Wäsch R, Becker H, May AM, Duyster J, Hackanson B, Ganser A, Döhner H, Lübbert M. Rummelt C, et al. Among authors: becker h. Haematologica. 2023 Aug 1;108(8):2244-2248. doi: 10.3324/haematol.2022.282258. Haematologica. 2023. PMID: 36601981 Free PMC article. Clinical Trial. No abstract available.
Progenitor-like cell type of an MLL-EDC4 fusion in acute myeloid leukemia.
Schuster LC, Syed AP, Tirier SM, Steiger S, Seufert I, Becker H, Duque-Afonso J, Ma T, Ogawa S, Mallm JP, Lübbert M, Rippe K. Schuster LC, et al. Among authors: becker h. Blood Adv. 2023 Nov 28;7(22):7079-7083. doi: 10.1182/bloodadvances.2022009096. Blood Adv. 2023. PMID: 37820244 Free PMC article. No abstract available.
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial.
Lübbert M, Wijermans PW, Kicinski M, Chantepie S, Van der Velden WJFM, Noppeney R, Griškevičius L, Neubauer A, Crysandt M, Vrhovac R, Luppi M, Fuhrmann S, Audisio E, Candoni A, Legrand O, Foà R, Gaidano G, van Lammeren-Venema D, Posthuma EFM, Hoogendoorn M, Giraut A, Stevens-Kroef M, Jansen JH, de Graaf AO, Efficace F, Ammatuna E, Vilque JP, Wäsch R, Becker H, Blijlevens N, Dührsen U, Baron F, Suciu S, Amadori S, Venditti A, Huls G; EORTC Leukemia Group, GIMEMA, and German MDS Study Group. Lübbert M, et al. Among authors: becker h. Lancet Haematol. 2023 Nov;10(11):e879-e889. doi: 10.1016/S2352-3026(23)00273-9. Lancet Haematol. 2023. PMID: 37914482 Free article. Clinical Trial.
Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype.
Thomas J, Rehman UU, Bresser H, Grishina O, Pfeifer D, Sollier E, Döhner K, Plass C, Becker H, Schmoor C, de Wit M, Lübbert M. Thomas J, et al. Among authors: becker h. Clin Epigenetics. 2024 Sep 11;16(1):126. doi: 10.1186/s13148-024-01737-4. Clin Epigenetics. 2024. PMID: 39261919 Free PMC article.
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.
Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman UU, Crysandt M, Jost E, Thol F, Heuser M, Götze KS, Schlenk RF, Salih HR, Schittenhelm MM, Heil G, Schwaenen C, Müller-Tidow C, Brugger W, Kündgen A, de Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, May AM, Wäsch R, Duyster J, Döhner K, Ganser A, Döhner H, Hackanson B, Becker H, Lübbert M. Bresser H, et al. Among authors: becker h. Eur J Haematol. 2024 Oct 13. doi: 10.1111/ejh.14304. Online ahead of print. Eur J Haematol. 2024. PMID: 39400388
A novel recurrent AML1-ETO fusion: tight in vivo association with BCR-ABL1.
Solari L, Bauer T, Dicker F, Haferlach C, Grießhammer M, Schnittger S, Becker H, Lübbert M. Solari L, et al. Among authors: becker h. Leukemia. 2013 Jun;27(6):1397-400. doi: 10.1038/leu.2013.53. Epub 2013 Feb 21. Leukemia. 2013. PMID: 23426164 No abstract available.
Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model.
Langhammer M, Schöpf J, Jaquet T, Horn K, Angel M, Spohr C, Christen D, Uhl FM, Maié T, Jacobi H, Feyerabend TB, Huber J, Panning M, Sitaru C, Costa I, Zeiser R, Aumann K, Becker H, Braunschweig T, Koschmieder S, Shoumariyeh K, Huber M, Schemionek-Reinders M, Brummer T, Halbach S. Langhammer M, et al. Among authors: becker h. Leukemia. 2023 Jul;37(7):1474-1484. doi: 10.1038/s41375-023-01916-x. Epub 2023 May 9. Leukemia. 2023. PMID: 37161070 Free PMC article.
2,960 results